What postoperative glucocorticoid dosing and cortisol monitoring protocol should be used for a patient who underwent pituitary surgery for Cushing's disease while taking osilodrostat (Isturisa) up to the day of surgery?

Postoperative Glucocorticoid Management After Pituitary Surgery for Cushing's Disease with Preoperative Osilodrostat

This patient requires immediate high-dose intravenous hydrocortisone replacement starting at induction, followed by continuous infusion postoperatively, with careful monitoring for both hypocortisolism and the potential for persistent remission.

Immediate Perioperative Protocol

At induction: Administer hydrocortisone 100 mg intravenously, followed immediately by continuous infusion of hydrocortisone 200 mg/24 hours 1. This follows established guidelines for patients with adrenal insufficiency undergoing major surgery under anesthesia.

Postoperative management:

• Continue hydrocortisone 200 mg/24 hours by IV infusion while nil by mouth (alternatively, hydrocortisone 50 mg every 6 hours intramuscularly) 1
• Once tolerating oral intake, transition to double the usual replacement dose of oral hydrocortisone for 48 hours, then continue for up to a week following major surgery 1

Critical Monitoring Considerations

Early Cortisol Assessment (Days 1-3)

Morning of postoperative day 1: Check serum cortisol before any glucocorticoid administration. A cortisol >400 nmol/L (>14.5 µg/dL) has 90.9% positive predictive value for intact HPA axis function 2. However, in this specific scenario with preoperative osilodrostat use, interpretation requires extreme caution.

Key caveat: Recent evidence shows that 33-50% of Cushing's disease patients develop cortisol <138 nmol/L (<5.0 µg/dL) by postoperative days 1-3 even without perioperative glucocorticoid coverage 3. The osilodrostat adds complexity because:

• Cortisol suppression may persist beyond osilodrostat's 4-hour half-life 4
• Rapid cortisol fluctuations from osilodrostat can precipitate psychiatric symptoms including delirium, even with hydrocortisone supplementation 5
• Early hypocortisolism with sustained remission has been documented after brief osilodrostat therapy 6

Unique Risk: Paradoxical Sustained Remission

Monitor for unexpected prolonged eucortisolism: In rare cases, brief osilodrostat exposure before surgery can result in sustained biochemical remission lasting >20 months after drug discontinuation 6. This means:

• Do not assume immediate return of hypercortisolism postoperatively
• Serial cortisol monitoring is essential even after glucocorticoid weaning
• Some patients may achieve durable remission without requiring long-term replacement

Glucocorticoid Weaning Protocol

Week 1-2 postoperatively:

• Continue stress-dose coverage (double replacement doses)
• Check morning serum cortisol and 24-hour urine free cortisol before morning dose
• Monitor for clinical signs of hypocortisolism: nausea, vomiting, fatigue, abdominal pain, dizziness, hypotension 4

Week 2-6:

• If morning cortisol remains <138 nmol/L (<5 µg/dL) with symptoms, continue replacement hydrocortisone 10 mg twice daily
• If morning cortisol >138 nmol/L and asymptomatic, attempt gradual taper
• Perform short synacthen test (SST) at 6 weeks to assess HPA axis recovery 2

Beyond 6 weeks:

• In Cushing's disease patients, first cortisol >138 nmol/L typically occurs around 129 days postoperatively, with glucocorticoid discontinuation around 402 days 3
• However, osilodrostat pretreatment may alter this timeline unpredictably 6
• Continue monitoring every 1-2 months until HPA axis recovery confirmed

Special Monitoring for Osilodrostat-Specific Complications

Psychiatric symptoms: Watch for depressive symptoms, depersonalization, delirium, or altered consciousness—these can occur with both cortisol elevation and rapid cortisol reduction 5. Close collaboration with psychiatry may be necessary.

Electrolyte monitoring: Although osilodrostat can cause hypokalemia through mineralocorticoid precursor accumulation 4, postoperative patients typically show improvement in potassium levels as hypercortisolism resolves 7.

ACTH monitoring: Check ACTH levels during follow-up, as progressive ACTH elevation may indicate incomplete tumor resection requiring additional intervention 8.

Common Pitfalls to Avoid

1. Blanket glucocorticoid coverage without assessment: While guidelines support stress-dose steroids 1, recent data suggest some Cushing's patients may not require perioperative coverage 3. However, given the surgical stress and osilodrostat's unpredictable effects, err on the side of coverage initially.

2. Premature glucocorticoid discontinuation: The combination of recent osilodrostat use and surgical manipulation creates high risk for adrenal crisis. Maintain replacement until HPA axis recovery is biochemically confirmed.

3. Misinterpreting early postoperative cortisol levels: Day 1-2 cortisol measurements may be suppressed from osilodrostat effects rather than surgical cure. Serial measurements over weeks are more informative 8.

4. Overlooking sustained remission: Unlike typical postoperative courses, osilodrostat pretreatment may produce unexpectedly durable eucortisolism 6. Monitor for this possibility to avoid unnecessary long-term replacement.

The 2020 UK guidelines provide the most comprehensive perioperative steroid protocol 1, but the 2021 Cushing's disease consensus acknowledges that preoperative medical therapy complicates postoperative assessment 9. The FDA label for osilodrostat emphasizes that cortisol suppression can persist beyond drug half-life and requires vigilant monitoring 4.